CANSINOBIO (06185): PCV24 initiates Phase I/II clinical trials and completes the enrollment of the first subject.

CANSINOBIO (06185) announced that the Phase I/II clinical trials for the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/diphtheria toxin) (PCV24) developed by the company have officially commenced recently, with the first subject successfully enrolled. The PCV24 developed by the company received clinical trial approval from the China National Medical Products Administration (NMPA) in January 2026. The PCV24 of the company covers the main epidemic serotypes of pneumococcus, using a combination of polysaccharide antigens and protein carriers through covalent binding, as well as dual-carrier technology. It is intended for vaccination of individuals aged 2 months and above (minimum 6 weeks) to prevent infectious diseases caused by 24 serotypes of pneumococcus. The 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/diphtheria toxin) (trade name: Youpeixin) developed by the company received new drug application approval from the NMPA in June 2025. PCV24 is a further product layout of the company's pneumococcal product portfolio. As of the date of this announcement, there are no marketed products of the 24-valent pneumococcal polysaccharide conjugate vaccine domestically or internationally. The Phase I/II clinical trials are designed to evaluate the safety and immunogenicity of PCV24 when administered in individuals aged 2 months and above (minimum 6 weeks).